SOX2 and neoplasm: Although the tumor-promoting role of FOXO6 in adenocarcinoma has not been reported, this TF was previously found to contribute to the resistance of erlotinib treatment in EGFR-mutant lung cancers by inducing the expression of SOX2 58.